Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Not a "POS". It's a clinical stage biotech in the middle of several mid to late stage successful trials, with three separate pipelines, where success with any one of their three drugs would rocket the share price of IPIX to the moon.
Hardly a poster child for a typical "pink sheet shell company". I mean seriously.
DOTB
POS? yes Point of Sale. We will all be ringing the register with much cash when IPIX get's to 50.00 or higher.
This POS just went red on the day like I predicted. It can't even get a close over .75.
this is by definition a pink sheet shell company controlled by MM's
Getting close folks. Big news coming soon.
Final Patient Completes Treatment in Innovation Pharmaceuticals Phase 2 Trial of Brilacidin for Preventing Oral Mucositis in Cancer Patients
GlobeNewswire•October 2, 2017Comment
BEVERLY, Mass., Oct. 02, 2017 (GLOBE NEWSWIRE) -- Innovation Pharmaceuticals Inc. (IPIX) (“the Company”), a clinical stage biopharmaceutical company, today announces that the last patient has completed study treatment in the Company’s Phase 2 clinical trial of Brilacidin for the prevention and treatment of severe Oral Mucositis (OM) in patients undergoing chemoradiation for Head and Neck Cancer. A total of 61 patients were enrolled in the double-blinded study.
One of the primary objectives of the study (see NCT02324335 ) is to evaluate the efficacy of Brilacidin in reducing the incidence of severe Oral Mucositis (WHO Grade ≥3) compared to placebo after seven weeks of study treatment. Another primary objective is to assess the safety and tolerability of Brilacidin.
Secondary objectives include evaluating the efficacy of Brilacidin in reducing the duration of severe OM (WHO Grade ≥3) and delaying the onset of severe OM (WHO Grade ≥3).
Interim results released earlier this year (see the March 27, 2017 press release) showed a markedly reduced rate of severe OM (WHO Grade ≥ 3) in patients treated with Brilacidin while undergoing chemoradiation and who received at least 55 Gy cumulative units of radiation.
“The final patient completing study treatment in this Phase 2 clinical trial is yet another achievement in the development of Brilacidin,” commented Arthur P. Bertolino, MD PhD, MBA, President and Chief Medical Officer at Innovation Pharmaceuticals. “Oral mucositis represents a significant treatment challenge to hundreds of thousands of patients and their team of doctors every year. Moreover, costs associated with managing OM place a substantial financial burden on our healthcare system due to a lack of safe and efficacious therapies to not only treat the condition, but prevent it. Over the coming weeks, patients will complete their per-protocol follow up visits after which time the study data will be unblinded. We believe a successful trial for this indication would be a medical breakthrough and likely generate significant interest as the market for a drug that can help prevent severe OM is estimated to be substantial.”
Oral Mucositis is a frequent, painful and debilitating complication of chemoradiation commonly manifesting in the treatment of Head and Neck Cancer. Characterized by inflammation and ulceration, patients suffering from OM are often unable to speak or eat (requiring the insertion of a feeding tube) and are more susceptible to bacterial infections, with severe cases leading to hospitalization and increased treatment costs of up to $25,000. There currently are no approved medications for the prevention of OM in this population, with only limited palliative care options available. Worldwide, the potential market for OM is expected to exceed $1 billion in the next few years.
The people have spoken and I will remove later today.
It's not. It's B.S. It needs to be removed.
I don't think this post is factual regarding IPIX. Why is it stickied?
BULLSHIT ! Most Relevant and Interesting ! WOW ! Not to REAL IPIX investors for sure.
GO IPIX !
What would you like me to sticky? I reviewed the last 48 hours of posts and I found the currently stickied post to be the most relevant/interesting for ipix investors.
Stickys should be reserved for important information about IPIX not your pet subjects.
Why do we have blatantly false information stickied on this board?
Obviously the statement in question isn't true and you're just too classy to say so. Fortunately I'm not similarly constrained.
This is obviously misinformation:
"The twice monthly FINRA report says There are uncovered shares (naked) which are listed as fail to deliver."
The twice monthly short interest report DOES quantify uncovered short positions, however it has nothing at all to do with naked short selling or failures to deliver.
I hope others read the following. In my case you were preaching to the choir.
http://investorshub.advfn.com/boards/replies.aspx?msg=135155054
And you wouldn't blame Leo for using funds that could go toward completing FDA trials? I think we all know the answer to that one. What a laugh.
the short interest folly could be put to bed with one simple PR from LEo:
"IPIX to do a stock buy back"
Short interest and sellers are a constant topic of interest, debate, and speculation for ipix investors.
about to go red on the day. what a POS
REGN to buy IPIX??? its halted.
10 billion coming up
I just glanced at a chart. Great news. In three months we'll be within 38 cents of the 52 week high, which by then will be about $1.10. Terrific!
Go IPIX!
this POS can't even hold .72. pathetic
how did this get stickied??????
LBK is spot on here. Anyone who has been around a while and pays attention to stock trading would concur. I believe those who constantly suggest that A RS is in shareholder interest know this, are disingenuous at the least, and are thus much more interested in facilitating a short sale and the SP declining then in it appreciating. "Everyone talks their book" is the equivalent of Colombo saying " follow the money".
Well said. Savvy management and outstanding science is going to turn the tables on the shorts. Go IPIX!!!
Yep and here's the most frustrating thing for non-investors, Leo Ehrlich understands this totally and is dealing with it like a pro.
GO IPIX - stay the course
Huh? Its not 10s of millions of short and naked short shares. It’s a few million short and only 1 million FTDs. A 1/10 reverse split would take the SP to $7 with a peak of $10. Short traders would hit that as hard as they could and drive it back under $5, which would kick in investment restrictions on institutional buyers. And that would lead to a sellingcascade to $2, and further institutional holding restrictions. I’ve seen it too many times.
If they can sell then you certainly should be able to sell
That’s because this is an investment stock and not a trading stock. You can’t expect an Egyptian mau kitten to act like that old tabby stray you found 12 years ago. Or, more to the point, you can’t expect a biopharma startup with 8 trials—6 in phase 2–to act like that piece of shit, high volume, trading stock that’s actually going to zero someday because they actually got nothing.
Sorry this post doesn't add up. The covering of tens of millions of naked short would cause a dramatic benefit far outweighing any strategizing by the legal shorts.
Unpin Nerby's prurisol inquiry. No validation, might be fake news
yeah - an ask that continually gets lowered. this POS can't even support a 3000 lot sell without it collapsing the stock.
when will anyone wake up and blame leo and mgmt for the failure to uplist and the tragic shareholder destruction
Of course you can’t sell a low volume stock at the ask, at least not without a lot of patience. Every experienced trader knows that. The ask is now getting hit. So, sell away.
its impossible to sell
What evidence do you have to support that?
and right on cue - they move the ask down. for 3000 shares!!!!!
Leo has created a roach motel where no one can sell but his buddies and Aspire
this stock is so pathetic, I can't even sell 2000 shares at the ask.
this is why Leo blundered the uplist - who wants to bother with an illiquid penny stock with wide spreads and crooked MM's?????????????????????
Terrific post! The logic and simplicity sums up why the longs have invested here.
If someone knows a pre income biotech stock about to enter multiple phase 3 and late stage 2 clinical trials with more potential than IPIX please let me know.
GLTA Farrell
Regardless of who pretends to know what I expect price and volume to forecast future success or not.Volume has to be close to a million and above.
The twice monthly FINRA report says There are uncovered shares (naked) which are listed as fail to deliver. It’s not conspiracy theory. It’s a fact that there are over 1 million uncovered IPIX shares
That is partially true. But if you go back and read his previous posts, the sensational Nerby Report was a response to the idea that "everyone know certain things even though the company never PR'd them." Specifically, the poster was suspicious of the idea that everyone knew, two weeks before the end of the quarter, that ipix wouldn't release interim P results simply because someone posted an email.
These negotiations IMO will be extremely complicated based on the potential of IPIX's pipeline. Do you agree? I would assume it could take years and also, as Leo has stated several times, the time to ink a deal and shake hands is after phase 2. That is when a company can maximize the value for a solid partnership.
However, lets discuss my first point. Just how complicated could this first deal be? Lets pretend that BP is in love with Brilacidin for UP/UC and the future Crohns. Lets pretend that single BP - lets call them Pfizer is also now interested in the OM side of Brilacidin as well. Pfizer has the CDA signed so they can look under the hood in more detail without mention and they are loving what they see. They have had their team investigate and do their DD on the drugs and again love it, however they are now more curious about the Anti-Fungal properties but do not want the Absssi anti-biotic portion, so they want to look further. Possibly BP 2 - lets call them Celgene is extremely interested in OM alone and will commit to a partnership based on the results of the phase 2 that will be released in 1 month. BP3 - lets call them J&J loves the topical application and continue to test the properties.
I am just thinking that so far the science has been SPOT ON - 100% successful and unbelievably promising. We know that Leo brought on Art to work with BP. We know that we have "MULTIPLE" CDA's signed. We know that the communication from Leo to shareholders has been harnessed. The PR's that we get are very limited and very straight forward for the past year or so.
I would love to sit down with Art, Leo and Dr. M and ask what their overall goal is, because at this point there are so many ways this can go from a partnership view, that I think we just have to sit tight wait for the phase 2 data coming in the next 3 months and see what happens after.
IMO - If Prurisol really outperforms Otezla, I would think that will be our first deal because it is pretty straightforward. As Georgiii says there could be many other applications for P, but for now we are just testing Psoriasis and that market is substantial especially looking for ORAL drugs.
just my morning coffee thoughts...
It's more a "hope you're right" type of message. Not one one can bank on.
"Coulds" and "ifs" on cusip and name changes forcing short covering don't equal will. How many shares do you own in certificate form? I would bet none of your IPIX shares are in certificate form.
The criminals who abusively naked short are much smarter than given credit for and do not willingly turn themselves in. IPIX will force the shorts to cover thanks to outstanding science and savvy management. Go IPPIX!!!
When you buy a share of XYZ, there is a record of it in your name (or your broker's name) at the DTC. If that company changes its CUSIP (or gets bought out, or whatever), the legitimate records at the DTC get updated. If you had an illegitimate record, you won't get the replacement shares. Eventually you or your broker would realize this, and raise hell.
Incidentally, how many of you have ever had this problem? None. That's because these "fake shares" and "naked shorts" are conspiracy theories and legends and don't actually happen. It's also why the SEC seems to be "in on the conspiracy" to such folks. No, the reason the SEC doesn't do anything is because there is no conspiracy. They're tired of getting letters from retail whack-jobs complaining about naked shorting.
EXCELLENT Cyber....THANKS !
GO IPIX !
The current Prurisol Phase 2b trial will be successfully completed within 90 days!!!
https://clinicaltrials.gov/ct2/show/NCT02949388?term=prurisol&rank=2
http://www.ipharminc.com/press-release/2017/8/28/innovation-pharmaceuticals-completes-full-patient-enrollment-in-phase-2b-study-of-prurisol-for-the-oral-treatment-of-psoriasis
Good luck and GOD bless,
George
Mgmt has been talking about BP for more than 2 years
Tic toc
No price appreciation despite big talk and cda
Tic toc
No price appreciation even based on any rumors - a lack of rumor in market indicates not much speculation by market
Tic toc
Price just keeps going down showing lack of credibility to what mgmt says
Tic toc
Followers
|
976
|
Posters
|
|
Posts (Today)
|
0
|
Posts (Total)
|
403528
|
Created
|
05/10/08
|
Type
|
Free
|
Moderators zandant sunspotter snayeman loanranger frenchbroad |
Innovation Pharmaceuticals Inc. (IPIX)
$IPIX NEWS - http://ipharminc.com/press-release
SEC Filings https://www.sec.gov/cgi-bin/browse-edgar?company=Innovation+Pharmaceutical&owner=exclude&action=getcompany
From the most recent 10-K:
There are doubts about our ability to continue as a going concern.
We have generated revenue of $0 and $18,000 for the fiscal years ended June 30, 2023 and 2022, respectively and have an accumulated deficit of $125.3 million through June 30, 2023. These factors raise substantial doubt about our ability to continue as a going concern.
We need to raise substantial additional capital in the future to fund our operations and we may be unable to raise such funds when needed and on acceptable terms, which could prevent us from fully implementing our business, operating and development plans.
We currently have an approximate $1.0 million cash balance as of the date of this filing, but that is insufficient to complete the development and commercialization of any of our proposed products. We expect to incur costs of approximately $1.8 million in the upcoming fiscal year ending June 30, 2024 to operate our business in accordance with our business plans and budgets.
We have limited experience in drug and formulation development, the conduct of clinical trials, and may not be able to successfully develop any drugs.
Development of pharmaceutical products is a risky and time-consuming process subject to a number of factors, many of which are outside of our control. We are subject to regulatory authority permissions and approvals, most importantly the FDA. Our drug candidate(s)/indications are at early and mid-stages of development. Consequently, we can provide no assurance of the successful and timely development of new drugs, and the failure to do so could cause us to cease operations.
We may elect to deregister our common stock under the Exchange Act and suspend our reporting obligations. Such deregistration and suspension would result in less disclosure about us and may negatively affect the liquidity and trading prices of our common stock.
http://www.ipharminc.com/
About Innovation Pharmaceuticals Inc.:
Established in 2007, and headquartered in Wakefield, Massachusetts, Innovation Pharmaceuticals Inc. (formerly Cellceutix Corporation) is a publicly traded biopharmaceutical company dedicated to discovering and advancing innovative medical therapies with dermatology, oncology, anti-inflammatory and antibiotic applications.
Through ongoing research and drug development efforts, Innovation is focused on improving the clinical care of patients, as well as growing shareholder value. Our team consists of a diverse and accomplished group of professionals working together toward achieving this common goal.
IPIX CEO - "The Company historically devoted most of its efforts and resources on business development, regulatory matters, and clinical trials. Presently, the Company does not have sufficient financial resources to advance our drug candidates meaningfully." "In general, we expect to concentrate on product development and engage in a limited way in product discovery, avoiding the significant investment of time and financial resources that is generally required for a promising compound to be identified and brought into clinical trials." Source - https://www.sec.gov/ix?doc=/Archives/edgar/data/1355250/000147793223003414/ipix_10q.htm
More information is available at http://www.ipharminc.com.
Management: http://www.ipharminc.com/senior-management/
Scientific Advisors: http://www.ipharminc.com/scientific-advisors/
Clinical Trials: https://clinicaltrials.gov/ct2/results?cond=&term=%22Innovation+Pharmaceuticals%2C+Inc.%22++&cntry=&state=&city=&dist=&Search=Search&flds=abcefgps
Trials under previous name: https://clinicaltrials.gov/ct2/results?cond=&term=cellceutix&cntry=&state=&city=&dist=&Search=Search&flds=abcefgps
Product Pipeline: http://www.ipharminc.com/therapeutic-areas/
Recent News and Press Releases:
https://finance.yahoo.com/quote/IPIX?p=IPIX
http://www.ipharminc.com/press-release/
SEC Filings (CIK:0001355250): https://www.sec.gov/cgi-bin/browse-edgar?company=Innovation+Pharmaceutical&owner=exclude&action=getcompany
Transfer Agent:
West Coast Stock Transfer, Inc.
721 N. Vulcan Ave. Ste. 205
Encinitas, CA 92024
(619) 664-4780 p
(760) 452-4423 f
cs@wcsti.com
http://www.westcoaststocktransfer.com
Share Structure: See SEC filing link above for current share structure
Investor Relations:
http://www.ipharminc.com/new-faq/
http://www.ipharminc.com/contact-us-1
Chart: https://stockcharts.com/h-sc/ui?s=IPIX
All messages, including iBox content, are the opinion of the posters, are no substitute for your own research, and should not be relied upon for stock trading or any other purpose.
Also, keep in mind that moderators may or may not have a position in said stock. Being a moderator isn’t a sign of endorsement.
Please keep your posts on topic because your message(s) will probably be deleted when:
* Posting content that's off-topic to the subject of this board;
* Posting statements that don't add value to the discussion; or
* When you violate any other posting term of the iHub User Agreement: http://investorshub.advfn.com/boards/complex_terms.asp
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |